0000000000286466

AUTHOR

Luis Ortega-paz

0000-0002-9567-3253

showing 8 related works from this author

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac…

2017

Aims: The aim of the study was to develop a scoring model to evaluate the quality of bioresorbable vascular scaffold (BVS) implantation and determine the model's usefulness in predicting adverse cardiac events. Methods and results: The implantation technique and clinical outcomes of 1,736 lesions treated with BVS were analysed using the GHOST-EU registry. Predilation, scaffold sizing, and post-dilation (PSP) were scored according to the hazard model derived from the weight of these variables. The primary end-point was a one-year device-oriented composite endpoint (DoCE) composed of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation. Def…

Target lesionBioresorbable scaffoldmedicine.medical_specialtyAntineoplastic Agents030204 cardiovascular system & hematologyRisk AssessmentClinical research03 medical and health sciencesBlood Vessel Prosthesis ImplantationOutcome Assessment (Health Care)0302 clinical medicinePostoperative ComplicationsTheoreticalBlood vessel prosthesisModelsInternal medicineOutcome Assessment Health CaremedicineHumans030212 general & internal medicineMyocardial infarctionEverolimusAdverse effectProspective cohort studyBioresorbable scaffolds; Clinical research; Risk stratification; Antineoplastic Agents; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Everolimus; Humans; Outcome Assessment (Health Care); Retrospective Studies; Risk Assessment; Tissue Scaffolds; Models Theoretical; Postoperative Complications; Cardiology and Cardiovascular MedicineRisk stratificationRetrospective StudiesEverolimusTissue Scaffoldsbusiness.industryRetrospective cohort studyModels Theoreticalmedicine.diseaseThrombosisSurgeryBlood Vessel ProsthesisCardiologyBioresorbable scaffoldsbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds…

2016

medicine.medical_specialtyScoring systemEverolimusbusiness.industry030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patient030212 general & internal medicineRadiologyCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldmedicine.drugJournal of the American College of Cardiology
researchProduct

Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.

2019

INTRODUCTION AND OBJECTIVES Cell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate the relationship between cfDNA and coronary reperfusion. METHODS We studied 116 patients treated with primary angioplasty using thrombus aspiration. Coronary (during aspiration) and peripheral (at the end of the procedure) blood samples were drawn for cfDNA, as well as high-sensitivity troponin T and myeloperoxidase quantification. The primary endpoint was no ST-segment resolution (STR) (≥ 70%) and the secondary endpoint was lack of final Thrombolysis In Myocardial Infarction flow 3 (TIMI 3). RESULTS…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial ReperfusionMyocardial Reperfusion Injury030204 cardiovascular system & hematologyLymphocyte ActivationLesion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionTroponin TInternal medicinemedicineClinical endpointLeukocytesST segmentHumanscardiovascular diseasesMyocardial infarctionProspective StudiesPeroxidaseTroponin Tbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedmedicine.diseaseTreatment OutcomeMicrovesselsCardiologyST Elevation Myocardial InfarctionFemalemedicine.symptombusinessCell-Free Nucleic AcidsTIMIRevista espanola de cardiologia (English ed.)
researchProduct

Circulating miRNA Fingerprint and Endothelial Function in Myocardial Infarction: Comparison at Acute Event and One-Year Follow-Up.

2022

MicroRNAs (miRNA) are major regulators of intercellular communication and key players in the pathophysiology of cardiovascular disease. This study aimed to determine the miRNA fingerprint in a cohort of 53 patients with acute myocardial infarction (AMI) with non-ST-segment elevation (NSTEMI) relative to miRNA expression in healthy controls (n = 51). miRNA expression was initially profiled by miRNA array in the serum of patients undergoing cardiac catheterization during NSTEMI (n = 8) and 1 year past the event (follow-up, n = 8) and validated in the entire cohort. In total, 58 miRNAs were differentially expressed during AMI (p < 0.05), while 36 were modified at follow-up (Fisher’s exact t…

Fisiologia cel·lularMicroRNAsMyocardial InfarctionmicroRNA profile; serum biomarker; myocardial infarction; endothelial cell; let-7e; angiogenesisCytokinesEndothelial CellsHumansGeneral MedicineCirculating MicroRNAMalalties coronàriesNon-ST Elevated Myocardial InfarctionFollow-Up StudiesCells
researchProduct

ADN libre y daño microvascular en el infarto agudo de miocardio con elevación del segmento ST tratado con intervención coronaria primaria

2019

Resumen Introduccion y objetivos En el infarto agudo de miocardio con elevacion del segmento ST, el ADN libre circulante podria originarse de los leucocitos activados en la lesion coronaria. El objetivo fue investigar la relacion entre el ADN libre y la reperfusion coronaria. Metodos Se incluyo a 116 pacientes, tratados con angioplastia primaria y tromboaspiracion. Se cuantifico el ADN libre coronario (durante la aspiracion) y periferico (al final del procedimiento), asi como la troponina T ultrasensible y la mieloperoxidasa. El objetivo primario fue la no resolucion del segmento ST (RST) (≥ 70%) y el secundario la ausencia de flujo Thrombolysis In Myocardial Infarction 3 (TIMI 3) final. Re…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis

2020

AbstractDespite the promising value of miRNAs in the diagnostic and prognostic of cardiovascular disease (CVD), recent meta-analyses did not support their potential. Methodological variances in studies may interfere with miRNA profile and affect their results. This study determines if the blood starting material is a source of variance in miRNA profile by performing a paired comparison in plasma and serum of the expression of primary miRNAs associated with CVD. Circulating miRNA yield was similar in both plasma and serum, although a significant increase was observed in patients with Non-ST-elevation myocardial infarction (NSTEMI) compared to control volunteers. When normalized by the expres…

0301 basic medicineCirculating mirnasMaleMicro RNAsMyocardial InfarctionOld agelcsh:MedicineGene Expression030204 cardiovascular system & hematologyBlood plasmaPlasma0302 clinical medicineMyocardial infarctionlcsh:ScienceNon-ST Elevated Myocardial InfarctionMultidisciplinaryMiddle AgedPrognosisVellesamiRNAsFemalemedicine.medical_specialtyPaired comparisonFisiologiaPredictive markersArticle03 medical and health sciencesMirna expressionInternal medicinemicroRNAmedicineHumansIn patientCorCirculating MicroRNAAgedbusiness.industrylcsh:RPlasma sanguinimedicine.diseaseInfart de miocardiMicroRNAsMyocardial infarction030104 developmental biologyEndocrinologyROC Curvelcsh:QbusinessTranscriptomeBiomarkers
researchProduct

Effect of implantation technique on outcomes in patients receiving bioresorbable scaffolds in various clinical scenarios

2021

ABSTRACT Introduction and objectives: The PSP (pre-dilation, sizing and post-dilation) score, derived from the GHOST-EU registry, has evaluated the relationship between the implantation technique of bioresorbable scaffolds and the clinical outcomes. The objective was to perform an external validation of the PSP technique and to determine its effect on adverse cardiac events in various clinical and anatomical scenarios. Methods: Data from the REPARA registry (2230 patients) were used for external validation, whereas a common database combining REPARA and GHOST-EU (3250 patients) data was used to evaluate the effect of PSP technique in various clinical and anatomical scenarios. PSP-1 and PSP-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentRPercutaneous coronary interventionmedicine.diseaseCoronary artery diseaseeye diseasesPercutaneous coronary interventionSurgeryCoronary artery diseaseBioresorbable vascular scaffoldsBioresorbable scaffoldsmedicineMedicineIn patientCardiology and Cardiovascular MedicinebusinessBioresorbable scaffoldREC: interventional cardiology (English Edition)
researchProduct